Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Annovis Bio Inc.
< Previous
1
2
Next >
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
October 29, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis to Attend the CTAD 2026 with Three Presentations
October 22, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
September 23, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis to Host Corporate Update Webinar on September 2, 2026
August 25, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
August 14, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
July 07, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
July 01, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Bio Regains NYSE Listing Compliance
May 26, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
May 20, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
May 19, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
May 15, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
May 07, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
April 28, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
April 10, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
April 09, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
April 02, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Publishes Historical Review of Buntanetap in The Scientist
March 31, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
March 19, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
March 16, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
March 03, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
February 12, 2026
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
December 18, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis to Host Corporate Update Webinar on January 28, 2026
December 16, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
December 03, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces Two Presentations at the CTAD 2025 Conference
November 24, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
November 18, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
November 17, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
November 12, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
November 06, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
October 27, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
